FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894779831> ?p ?o ?g. }

• W2894779831 endingPage "61" @default.
• W2894779831 startingPage "51" @default.
• W2894779831 abstract "In renal cell carcinoma (RCC), angiopoietin (Ang) 2 is elevated at the time of progression on anti-vascular endothelial growth factor (VEGF) therapy and may contribute to resistance.We tested trebananib, an Ang 1 and 2 neutralizing peptibody in patients with RCC progressing on anti-VEGF treatment.Patients with measurable RCC progressing despite an anti-VEGF agent within 12 weeks, any number of prior treatments, and good PS were randomized to trebananib 15 mg/kg IV weekly without (Arm A) or with (Arm B) continuation of the prior anti-VEGF agent. The primary endpoint for each arm was tumor response (RECIST 1.1). Secondary endpoints included progression free survival and adverse events.Of 41 enrolled patients, 35 were eligible and started treatment (17 Arm A, 18 Arm B) with median age 60 (46-76) and 3 prior treatments (1-8). Four died prior to documented progression and 27 progressed as their first event. Both arms were stopped after interim analysis, 2 responses (11%; 95% C.I. 1-35%) were observed in Arm B. Median PFS of 2.7 (95% C.I. 2.3-4.7) months in Arm A and 5.2 (95% C.I. 2.7-10.8) months in Arm B did not support continued study. Common adverse events including fatigue, nausea, and increased creatinine were generally grade 1-2 and numerically higher in Arm B. The most common grade 3 or higher adverse events were hypertension and dyspnea.While tolerable, trebananib either without or with continued anti-VEGF therapy did not show promising activity in RCC patients who recently progressed on anti-VEGF therapy alone." @default.
• W2894779831 created "2018-10-12" @default.
• W2894779831 creator A5010265482 @default.
• W2894779831 creator A5010848347 @default.
• W2894779831 creator A5016991744 @default.
• W2894779831 creator A5029144224 @default.
• W2894779831 creator A5031088617 @default.
• W2894779831 creator A5036091074 @default.
• W2894779831 creator A5041033274 @default.
• W2894779831 creator A5067387322 @default.
• W2894779831 creator A5073593424 @default.
• W2894779831 creator A5075799959 @default.
• W2894779831 date "2019-02-05" @default.
• W2894779831 modified "2023-10-16" @default.
• W2894779831 title "Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib – Results of NCI/CTEP Protocol 9048" @default.
• W2894779831 cites W1935873602 @default.
• W2894779831 cites W1968014316 @default.
• W2894779831 cites W1982110083 @default.
• W2894779831 cites W1990378122 @default.
• W2894779831 cites W1996859043 @default.
• W2894779831 cites W2000975023 @default.
• W2894779831 cites W2017322644 @default.
• W2894779831 cites W2019607817 @default.
• W2894779831 cites W2028656738 @default.
• W2894779831 cites W2074138172 @default.
• W2894779831 cites W2081596239 @default.
• W2894779831 cites W2095235698 @default.
• W2894779831 cites W2096415778 @default.
• W2894779831 cites W2099028752 @default.
• W2894779831 cites W2110943754 @default.
• W2894779831 cites W2122927195 @default.
• W2894779831 cites W2123312554 @default.
• W2894779831 cites W2134131507 @default.
• W2894779831 cites W2141674582 @default.
• W2894779831 cites W2159731526 @default.
• W2894779831 cites W2160373161 @default.
• W2894779831 cites W2160724351 @default.
• W2894779831 cites W2166215138 @default.
• W2894779831 doi "https://doi.org/10.3233/kca-180041" @default.
• W2894779831 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6400131" @default.
• W2894779831 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30854497" @default.
• W2894779831 hasPublicationYear "2019" @default.
• W2894779831 type Work @default.
• W2894779831 sameAs 2894779831 @default.
• W2894779831 citedByCount "7" @default.
• W2894779831 countsByYear W28947798312020 @default.
• W2894779831 countsByYear W28947798312021 @default.
• W2894779831 countsByYear W28947798312022 @default.
• W2894779831 countsByYear W28947798312023 @default.
• W2894779831 crossrefType "journal-article" @default.
• W2894779831 hasAuthorship W2894779831A5010265482 @default.
• W2894779831 hasAuthorship W2894779831A5010848347 @default.
• W2894779831 hasAuthorship W2894779831A5016991744 @default.
• W2894779831 hasAuthorship W2894779831A5029144224 @default.
• W2894779831 hasAuthorship W2894779831A5031088617 @default.
• W2894779831 hasAuthorship W2894779831A5036091074 @default.
• W2894779831 hasAuthorship W2894779831A5041033274 @default.
• W2894779831 hasAuthorship W2894779831A5067387322 @default.
• W2894779831 hasAuthorship W2894779831A5073593424 @default.
• W2894779831 hasAuthorship W2894779831A5075799959 @default.
• W2894779831 hasBestOaLocation W28947798311 @default.
• W2894779831 hasConcept C126322002 @default.
• W2894779831 hasConcept C126894567 @default.
• W2894779831 hasConcept C141071460 @default.
• W2894779831 hasConcept C143998085 @default.
• W2894779831 hasConcept C167734588 @default.
• W2894779831 hasConcept C168563851 @default.
• W2894779831 hasConcept C197934379 @default.
• W2894779831 hasConcept C203092338 @default.
• W2894779831 hasConcept C2776694085 @default.
• W2894779831 hasConcept C2777025900 @default.
• W2894779831 hasConcept C2777472916 @default.
• W2894779831 hasConcept C2777802072 @default.
• W2894779831 hasConcept C2778019345 @default.
• W2894779831 hasConcept C2778439243 @default.
• W2894779831 hasConcept C2778695046 @default.
• W2894779831 hasConcept C2779490328 @default.
• W2894779831 hasConcept C2780580376 @default.
• W2894779831 hasConcept C2780739268 @default.
• W2894779831 hasConcept C31760486 @default.
• W2894779831 hasConcept C535046627 @default.
• W2894779831 hasConcept C61943457 @default.
• W2894779831 hasConcept C71924100 @default.
• W2894779831 hasConceptScore W2894779831C126322002 @default.
• W2894779831 hasConceptScore W2894779831C126894567 @default.
• W2894779831 hasConceptScore W2894779831C141071460 @default.
• W2894779831 hasConceptScore W2894779831C143998085 @default.
• W2894779831 hasConceptScore W2894779831C167734588 @default.
• W2894779831 hasConceptScore W2894779831C168563851 @default.
• W2894779831 hasConceptScore W2894779831C197934379 @default.
• W2894779831 hasConceptScore W2894779831C203092338 @default.
• W2894779831 hasConceptScore W2894779831C2776694085 @default.
• W2894779831 hasConceptScore W2894779831C2777025900 @default.
• W2894779831 hasConceptScore W2894779831C2777472916 @default.
• W2894779831 hasConceptScore W2894779831C2777802072 @default.
• W2894779831 hasConceptScore W2894779831C2778019345 @default.
• W2894779831 hasConceptScore W2894779831C2778439243 @default.
• W2894779831 hasConceptScore W2894779831C2778695046 @default.

• next